mgi 114
Recently Published Documents

TOTAL DOCUMENTS

20
(FIVE YEARS 0)

H-INDEX

10
(FIVE YEARS 0)
Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors

2006 ◽  
Vol 47 (2) ◽  
pp. 163-168 ◽  
Author(s):  
Lisa R. Bomgaars ◽  
Gail C. Megason ◽  
Jeanette Pullen ◽  
Anne-Marie Langevin ◽  
Steve Dale Weitman ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Pediatric Patients ◽  
Mgi 114

Phase I trial of irofulven (MGI 114) plus docetaxel in advanced cancers

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 2042-2042
Author(s):  
F. R. Ahmann ◽  
S. Culine ◽  
G. Wilding ◽  
K. Papadopoulos ◽  
H. Raftopoulos ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Mgi 114

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer

Lung Cancer ◽  
2004 ◽  
Vol 45 (3) ◽  
pp. 387-392 ◽  
Author(s):  
Carol A. Sherman ◽  
James E. Herndon ◽  
Dorothy M. Watson ◽  
Mark R. Green
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Trial ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mgi 114

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

2004 ◽  
Vol 22 (3) ◽  
pp. 343-349 ◽  
Author(s):  
Russell J. Schilder ◽  
John A. Blessing ◽  
Michael L. Pearl ◽  
Peter G. Rose
Keyword(s):  
Endometrial Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Mgi 114

Phase II Study of MGI-114 Administered Intravenously for 5 Days Every 28 Days to Patients With Metastatic Colorectal Cancer

2003 ◽  
Vol 26 (2) ◽  
pp. 132-134 ◽  
Author(s):  
Sunita Dwivedy Nasta ◽  
Paulo M. Hoff ◽  
Christopher S. George ◽  
Marcus Neubauer ◽  
Steven C. Cohen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Mgi 114

Phase II Study of MGI-114 Administered Intravenously for 5 Days Every 28 Days to Patients With Metastatic Colorectal Cancer

2003 ◽  
Vol 26 (2) ◽  
pp. 132-134
Author(s):  
Sunita Dwivedy Nasta ◽  
Paulo M. Hoff ◽  
Christopher S. George ◽  
Marcus Neubauer ◽  
Steven C. Cohen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Mgi 114

In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours

2001 ◽  
Vol 37 (11) ◽  
pp. 1419-1428 ◽  
Author(s):  
Y. Sato ◽  
S. Kashimoto ◽  
J.R. MacDonald ◽  
K. Nakano
Keyword(s):  
Human Tumour ◽  
Human Tumour Xenograft ◽  
Mgi 114 ◽  
Tumour Xenograft ◽  
Xenograft Models

Phase I study of MGI 114 (irofulven) exploring 3 different iv schedules (SCH) as a 5 minute infusion in advanced solid tumors (AST): final results

2001 ◽  
Vol 37 ◽  
pp. S71
Author(s):  
J. Alexandre ◽  
S. Chieze ◽  
E. Raymond ◽  
E. Brain ◽  
M. Ould Kaci ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Mgi 114

Phase I study of MGI 114 (Irofulven) given as either D1, D8 q3 weeks or D1, D5 q4 weeks schedule (sch) as a 30 minute infusion in advanced solid tumors (AST): preliminary results

2001 ◽  
Vol 37 ◽  
pp. S72-S73
Author(s):  
E. Raymond ◽  
J. Alexandre ◽  
E. Brain ◽  
S. Faivre ◽  
M. Ould Kaci ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Preliminary Results ◽  
Mgi 114

MGI 114: Augmentation of Antitumor Activity When Combined With Topotecan

2000 ◽  
Vol 22 (4) ◽  
pp. 306-314 ◽  
Author(s):  
Steven Weitman ◽  
Hector Barrera ◽  
Rodney Moore ◽  
Cristina Gonzalez ◽  
Jennifer Marty ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Mgi 114
Load More ...
Sign in / Sign up

Export Citation Format

Share Document